Assessment and hormonal management of osteoporosis

References

• Cummings SR, Black DM, Rubin SM. Lifetime risks of hip, Colles, or vertebral fracture and coronary heart disease among white postmenopausal women. Arch Intern Med 1989;149:2445–8
   PubMed Web of Science ®Google Scholar
• Black DM, Cummings SR, Genant HK, et al. Axial and appendicular bone density predict fractures in older women. J Bone Miner Res 1992;7:633–8
   PubMed Web of Science ®Google Scholar
• Marshall D, Johnell O, Wedel H. Meta-analysis of how well measures of bone mineral density predict occurrence of osteoporotic fractures. BMJ 1996;312:1254–9
   PubMed Web of Science ®Google Scholar
• Taylor BC, Schreiner PJ, Stone KL, et al. Long-term prediction of incident hip fracture risk in elderly white women: study of osteoporotic fractures. J Am Geriatr Soc 2004;52:1479–1486
   PubMed Web of Science ®Google Scholar
• Kanis JA, Johnell O, Oden A, et al. Ten year probabilities of osteoporotic fractures according to BMD and diagnostic thresholds. Osteoporos Int 2001;12:989–995
   PubMed Web of Science ®Google Scholar
• Kanis JA, Johnell O, Oden A, et al. FRAX™ and the assessment of fracture probability in men and women from the UK. Osteoporos Int 2008;19:385–397
   PubMed Web of Science ®Google Scholar
• Kanis JA, McCloskey E, Johansson H, et al. Case finding for the management of osteoporosis with FRAX-assessment and intervention thresholds for the UK. Osteoporos Int 2008;19:1395–1408
   PubMed Web of Science ®Google Scholar
• Jiang X, Gruner M, Trémollieres F, et al. Diagnostic accuracy of FRAX in predicting the 10-year risk of osteoporotic fractures using the USA treatment thresholds: a systematic review and meta-analysis. Bone 2017;99:20–25
   PubMed Web of Science ®Google Scholar
• Abrahamsen B, Vestergaard P, Rud B, et al. Ten-year absolute risk of osteoporotic fractures according to BMD T score at menopause: the Danish Osteoporosis Prevention Study. J Bone Miner Res 2006;21:796–800
   PubMed Web of Science ®Google Scholar
• Tremollieres F, Pouillès JM, Drewniak N, et al. Fracture risk prediction using BMD and clinical risk factors in early postmenopausal women: sensitivity of the WHO FRAX tool. J Bone Miner Res 2010;25:1000–1002
   Web of Science ®Google Scholar
• Writing Group for the Women’s Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women’s Health Initiative randomized controlled trial. JAMA 2002;288:321–333
   PubMed Web of Science ®Google Scholar
• US Preventive Services Task Force, Grossman DC, Curry SJ, et al. Hormone therapy for the primary prevention of chronic conditions in postmenopausal women: US Preventive Services Task Force recommendation statement. JAMA 2017;318:2224–3
   PubMed Web of Science ®Google Scholar
• Akhter MP, Lappe JM, Davies KM, et al. Transmenopausal changes in the trabecular bone structure. Bone 2007;41:111–8
   PubMed Web of Science ®Google Scholar
• Wehrli FW, Ladinsky GA, Jones C, et al. In vivo magnetic resonance detects rapid remodeling changes in the topology of the trabecular bone network after menopause and the protective effect of estradiol. J Bone Miner Res 2008;23:730–740
   PubMed Web of Science ®Google Scholar
• Sowers MR, Greendale GA, Bondarenko I, et al. Endogenous hormones and bone turnover markers in pre- and perimenopausal women: SWAN. Osteoporos Int 2003;14:191
   PubMed Web of Science ®Google Scholar
• Greendale GA, Sowers M, Han W, et al. Bone mineral density loss in relation to the final menstrual period in a multiethnic cohort: results from the Study of Women’s Health Across the Nation (SWAN). J Bone Miner Res 2012;27:111–8
   PubMed Web of Science ®Google Scholar
• Guthrie JR, Ebeling PR, Hopper JL, et al. A prospective study of bone loss in menopausal Australian-born women. Osteoporos Int 1998;8:282–290
   PubMed Web of Science ®Google Scholar
• Sowers M, Crutchfield M, Bandekar R, et al. Bone mineral density and its change in pre-and perimenopausal white women: the Michigan Bone Health Study. J Bone Miner Res 1998;13:1134–1140
   PubMed Web of Science ®Google Scholar
• Finkelstein JS, Brockwell SE, Mehta V, et al. Bone mineral density changes during the menopause transition in a multiethnic cohort of women. J Clin Endocrinol Metab 2008;93:861–8
   PubMed Web of Science ®Google Scholar
• Recker R, Lappe J, Davies K, et al. Characterization of perimenopausal bone loss: a prospective study. J Bone Miner Res 2000;15:1965–1973
   PubMed Web of Science ®Google Scholar
• Tremollieres FA, Pouilles JM, Ribot C. Vertebral postmenopausal bone loss is reduced in overweight women: a longitudinal study in 155 early postmenopausal women. J Clin Endocrinol Metab 1993;77:683–6
   PubMed Web of Science ®Google Scholar
• Saarelainen J, Kiviniemi V, Kröger H, et al. Body mass index and bone loss among postmenopausal women: the 10-year follow-up of the OSTPRE cohort. J Bone Miner Metab 2012;30:208–216
   PubMed Web of Science ®Google Scholar
• Siris ES, Brenneman SKE, Barrett-Connor E, et al. The effect of age and bone mineral density on the absolute, excess, and relative risk of fracture in postmenopausal women aged 50–99: results from the National Osteoporosis Risk Assessment (NORA). Osteoporos Int 2006;17:565–574
   PubMed Web of Science ®Google Scholar
• Black DM, Cooper C. Epidemiology of fractures and assessment of fracture risk. Clin Lab Med 2000; 20:439–453
   PubMed Web of Science ®Google Scholar
• Huopio J, Kröger H, Honkanen R, et al. Risk factors for perimenopausal fractures: a prospective study. Osteoporos Int 2000;11:219–227
   PubMed Web of Science ®Google Scholar
• Slemenda CW, Hu SL, Longcope C, et al. Predictors of bone mass in perimenopausal women. A prospective study of clinical data using photon absorptiometry. Ann Intern Med 1990;112:96–110
   PubMed Web of Science ®Google Scholar
• Hanson MA, Overgaard K, Riis BJ, et al. Potential risk factors for development of postmenopausal osteoporosis examined over a 12-year period. Osteoporosis Int 1991;1:95–102
   PubMedGoogle Scholar
• Ribot C, Pouilles JM, Bonneu M, et al. Assessment of the risk of postmenopausal osteoporosis using clinical factors. Clin Endocrinol 1992;36:225–228
   PubMed Web of Science ®Google Scholar
• Crandall CJ, Larson JC, Watts NB, et al. Comparison of fracture risk prediction by the US Preventive Services Task Force Strategy and two alternative strategies in women 50–64 years old in the Women’s Health Initiative. J Clin Endocrinol Metab 2014;99:4514–4522
   PubMed Web of Science ®Google Scholar
• Chen YT, Miller PD, Barrett-Connor E, et al. An approach for identifying postmenopausal women age 50–64 years at increased short-term risk for osteoporotic fracture. Osteoporos Int 2007;18:1287–1296
   PubMed Web of Science ®Google Scholar
• Stewart A, Kumar V, Reid DM. Long-term fracture prediction by DXA and QUS: a 10-year prospective study. J Bone Miner Res 2005;21:413–418
   PubMed Web of Science ®Google Scholar
• Johnell O, Kanis JA, Oden A, et al. Predictive value of BMD for hip and other fractures. J Bone Miner Res 2005;20:1185–1194
   PubMed Web of Science ®Google Scholar
• Garnero P, Dargent-Molina P, Hans D, et al. Do markers of bone resorption add to bone mineral density and ultrasonographic heel measurement for the prediction of hip fracture in elderly women? The EPIDOS prospective study. Osteoporos Int 1998;8:563–9
   PubMed Web of Science ®Google Scholar
• Bauer DC, Sklarin PM, Stone KL, et al. Biochemical markers of bone turnover and prediction of hip bone loss in older women: the study of osteoporotic fractures. J Bone Miner Res 1999;14:1404–1410
   PubMed Web of Science ®Google Scholar
• Ross PD, Kress BC, Parson RE, et al. Serum bone alkaline phosphatase and calcaneus bone density predict fractures: a prospective study. Osteoporos Int 2000;11:76–82
   PubMed Web of Science ®Google Scholar
• Garnero P, Sornay-Rendu E, Claustrat B, et al. Biochemical markers of bone turnover, endogenous hormones and the risk of fractures in postmenopausal women: the OFELY study. J Bone Miner Res 2000;15:1526–1536
   PubMed Web of Science ®Google Scholar
• Sornay-Rendu E, Munoz F, Garnero P, et al. Identification of osteopenic women at high risk of fracture: the OFELY study. J Bone Miner Res 2005;20:1813–1819
   PubMed Web of Science ®Google Scholar
• Cauley JA, Robbins J, Chen Z, et al. Effects of estrogen plus progestin on risk of fracture and bone mineral density: the Women’s Health Initiative randomized trial. JAMA 2003;290:1729–1738
   PubMed Web of Science ®Google Scholar
• Jackson RD, Wactawski-Wende J, LaCroix AZ, et al. Effects of conjugated equine estrogen on risk of fractures, and BMD in postmenopausal women with hysterectomy: results from the Women’s Health Initiative randomized trial. J Bone Miner Res 2006;21:817–828
   PubMed Web of Science ®Google Scholar
• Zhu L, Jiang X, Sun Y, et al. Effect of hormone therapy on the risk of bone fractures: a systematic review and metaanalysis of randomized controlled trials. Menopause 2016;23:461–470
   PubMed Web of Science ®Google Scholar
• Canonico M, Oger E, Plu-Bureau G, et al. Estrogen and Thromboembolism Risk (ESTHER) Study Group. Hormone therapy and venous thromboembolism among postmenopausal women: impact of the route of estrogen administration and progestogens: the ESTHER study. Circulation 2007;115:840–845
   PubMed Web of Science ®Google Scholar
• Renoux C, Dell, aniello S, Garbe E, et al. Transdermal and oral hormone replacement therapy and the risk of stroke: a nested case-control study. BMJ 2010;340:c2519
   PubMed Web of Science ®Google Scholar
• West SG, Hinderliter AL, Wells EC, et al. Transdermal estrogen reduces vascular resistance and serum cholesterol in postmenopausal women. Am J Obstet Gynecol 2001;184:926–933
   PubMed Web of Science ®Google Scholar
• Cacciatore B, Paakkari I, Hasselblatt R, et al. Randomized comparison between orally and transdermally administered hormone replacement therapy regimens of long-term effects on 24-hour ambulatory blood pressure in postmenopausal women. Am J Obstet Gynecol 2001;184:904–909
   PubMed Web of Science ®Google Scholar
• Anderson GL, Limacher M, Assaf AR, et al. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women’s Health Initiative randomized controlled trial. JAMA 2004;291:1701–1712
   PubMed Web of Science ®Google Scholar
• Anderson GL, Chlebowski RT, Aragaki AK, et al. Conjugated equine oestrogen and breast cancer incidence and mortality in postmenopausal women with hysterectomy: extended follow-up of the Women’s Health Initiative randomised trial. Lancet Oncol 2012;13:476–486
   PubMed Web of Science ®Google Scholar
• Fournier A, Berrino F, Clavel-Chapelon F. Unequal risks for breast cancer associated with different hormone replacement therapies: results from the E3N cohort study. Breast Cancer Res Treat 2008;107:103–111
   PubMed Web of Science ®Google Scholar
• Cordina-Duverger E, Truong T, Anger A, et al. Risk of breast cancer by type of menopausal hormone therapy: a case-control study among post-menopausal women in France. PLoS One 2013; 8:e78016
   PubMed Web of Science ®Google Scholar
• Lyytinen H, Pukkala E, Ylikorkala O. Breast cancer risk in postmenopausal women using estradiol-progestogen therapy. Obstet Gynecol 2009;113:65–73
   PubMed Web of Science ®Google Scholar
• Manson JE, Aragaki AK, Rossouw JE, et al. Menopausal hormone therapy and long-term all-cause and cause-specific mortality: the Women’s Health Initiative randomized trials. JAMA 2017;318:927–938
   PubMed Web of Science ®Google Scholar
• de Villiers TJ, Hall JE, Pinkerton JV, et al. Revised global consensus statement on menopausal hormone therapy. Climacteric 2016;19:313–5
   PubMed Web of Science ®Google Scholar
• Ettinger B, Black DM, Mitlak BH, et al. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators. JAMA 1999;282:637–645
   PubMed Web of Science ®Google Scholar